Adicet Bio, Inc.
ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity inā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.66
Price-0.12%
$0.00
1Y
Price
Market Cap
$55.155m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$6.506m
-
1y CAGR-33.3%
3y CAGR+14.2%
5y CAGREarnings
-$118.636m
-1.3%
1y CAGR-29.3%
3y CAGR-25.1%
5y CAGREPS
-$1.31
+1.5%
1y CAGR-11.1%
3y CAGR-4.6%
5y CAGRBook Value
$133.372m
$162.972m
Assets$29.600m
Liabilities$15.358m
DebtDebt to Assets
9.4%
-0.1x
Debt to EBITDAFree Cash Flow
-$100.253m
-7.2%
1y CAGR-20.7%
3y CAGR-14.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company